Method of treating mantle cell lymphoma

Abstract

This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.

1 . A method of treating or inhibiting mantle cell lymphoma in a mammal in need thereof, which comprises providing to said mammal an effective amount of a CCI-779.  
     
     
         2 . The method according to  claim 1 , wherein the CCI-779 is administered intravenously.  
     
     
         3 . The method according to  claim 1 , wherein the CCI-779 is administered weekly for one to twelve months.  
     
     
         4 . The method according to  claim 1 , wherein the CCI-779 is administered at a dose of 10 to 100 mg per week.  
     
     
         5 . The method according to  claim 1 , wherein the CCI-779 is administered intravenously at a dose of 25 mg per week.  
     
     
         6 . The method according to  claim 1 , wherein CCI-779 is administered orally at a dose of 100 mg to 250 mg per week.  
     
     
         7 . A pharmaceutical composition useful in treating or inhibiting mantle cell lymphoma in a mammal in need thereof, the composition comprising a CCI-779 in unit dosage form in association with a pharmaceutically acceptable carrier.  
     
     
         8 . A pharmaceutical pack containing a course of treatment of mantle cell lymphoma for one individual mammal, said pack comprising a container having a unit of CCI-779 in a unit dosage form.  
     
     
         9 . The pharmaceutical pack according to  claim 8 , wherein said pack contains one to four units of CCI-779.